About Oxysterol-binding protein 2
Oxysterol-binding protein 2 (OSBP2) is a protein
from Homo sapiens identified by UniProt accession
Q969R2, 916 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | Oxysterol-binding protein 2 |
| UniProt accession | Q969R2 |
| Gene | OSBP2 |
| Organism | Homo sapiens |
| Length | 916 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q969R2-F1 | alphafold | PREDICTED | 70.18 | — |
Amino-acid sequence (916 residues)
MGKAAAPSRG GGCGGRSRGL SSLFTVVPCL SCHTAAPGMS ASTSGSGPEP KPQPQPVPEP ERGPLSEQVS EAVSEAVPRS EPVSETTSEP EPGAGQPSEL LQGSRPGSES SSGVGAGPFT KAASEPLSRA VGSATFLRPE SGSLPALKPL PLLRPGQAKT PLGVPMSGTG TTSSAPLALL PLDSFEGWLL KWTNYLKGYQ RRWFVLGNGL LSYYRNQGEM AHTCRGTINL STAHIDTEDS CGILLTSGAR SYHLKASSEV DRQQWITALE LAKAKAVRVM NTHSDDSGDD DEATTPADKS ELHHTLKNLS LKLDDLSTCN DLIAKHGAAL QRSLTELDGL KIPSESGEKL KVVNERATLF RITSNAMINA CRDFLELAEI HSRKWQRALQ YEQEQRVHLE ETIEQLAKQH NSLERAFHSA PGRPANPSKS FIEGSLLTPK GEDSEEDEDT EYFDAMEDST SFITVITEAK EDSRKAEGST GTSSVDWSSA DNVLDGASLV PKGSSKVKRR VRIPNKPNYS LNLWSIMKNC IGRELSRIPM PVNFNEPLSM LQRLTEDLEY HHLLDKAVHC TSSVEQMCLV AAFSVSSYST TVHRIAKPFN PMLGETFELD RLDDMGLRSL CEQVSHHPPS AAHYVFSKHG WSLWQEITIS SKFRGKYISI MPLGAIHLEF QASGNHYVWR KSTSTVHNII VGKLWIDQSG DIEIVNHKTN DRCQLKFLPY SYFSKEAARK VTGVVSDSQG KAHYVLSGSW DEQMECSKVM HSSPSSPSSD GKQKTVYQTL SAKLLWKKYP LPENAENMYY FSELALTLNE HEEGVAPTDS RLRPDQRLME KGRWDEANTE KQRLEEKQRL SRRRRLEACG PGSSCSSEEE KEADAYTPLW FEKRLDPLTG EMACVYKGGY WEAKEKQDWH MCPNIF
Explore Oxysterol-binding protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets